MX2018007493A - Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido. - Google Patents

Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido.

Info

Publication number
MX2018007493A
MX2018007493A MX2018007493A MX2018007493A MX2018007493A MX 2018007493 A MX2018007493 A MX 2018007493A MX 2018007493 A MX2018007493 A MX 2018007493A MX 2018007493 A MX2018007493 A MX 2018007493A MX 2018007493 A MX2018007493 A MX 2018007493A
Authority
MX
Mexico
Prior art keywords
hmwk
full length
molecular weight
scmed
differ
Prior art date
Application number
MX2018007493A
Other languages
English (en)
Spanish (es)
Inventor
Zhang Guodong
FAUCETTE Ryan
j sexton Daniel
Wu Jiang
M Mustafa Gul
SZEWC Mark
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of MX2018007493A publication Critical patent/MX2018007493A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • G01N30/7233Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N2030/022Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027Liquid chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • G01N2800/224Haemostasis or coagulation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2018007493A 2015-12-15 2016-12-15 Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido. MX2018007493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267734P 2015-12-15 2015-12-15
PCT/US2016/066936 WO2017106504A1 (en) 2015-12-15 2016-12-15 Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Publications (1)

Publication Number Publication Date
MX2018007493A true MX2018007493A (es) 2018-09-18

Family

ID=57794352

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007493A MX2018007493A (es) 2015-12-15 2016-12-15 Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido.
MX2023000773A MX2023000773A (es) 2015-12-15 2018-06-15 Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000773A MX2023000773A (es) 2015-12-15 2018-06-15 Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido.

Country Status (13)

Country Link
US (3) US11668718B2 (https=)
EP (2) EP3390439B1 (https=)
JP (4) JP7092669B2 (https=)
KR (2) KR102728491B1 (https=)
CN (1) CN108602877A (https=)
AU (3) AU2016372159B2 (https=)
CA (1) CA3008621A1 (https=)
CO (1) CO2018007216A2 (https=)
EA (1) EA201891414A1 (https=)
IL (4) IL312919B2 (https=)
MX (2) MX2018007493A (https=)
NZ (1) NZ743482A (https=)
WO (1) WO2017106504A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
KR20240133761A (ko) 2015-10-19 2024-09-04 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
WO2018225830A1 (ja) * 2017-06-08 2018-12-13 国立大学法人宮崎大学 肺がんの検出方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
JP2603487B2 (ja) 1987-11-26 1997-04-23 大日本製薬株式会社 ガンに罹患している疑いのあるヒトをスクリーニングする方法
JPH08208692A (ja) 1994-09-28 1996-08-13 Sumitomo Pharmaceut Co Ltd 新規な細胞接着抑制ペプチド誘導体
JP3073439B2 (ja) * 1996-02-08 2000-08-07 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1044012B1 (en) 1998-11-10 2006-05-03 Temple University of the Commonwealth System of Higher Education Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
US20060154319A1 (en) 1999-04-29 2006-07-13 Flodgaard Hans J Inhibition of bradykinin release
WO2001034195A1 (en) 1999-11-12 2001-05-17 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
CA2478962A1 (en) 2002-03-15 2003-09-25 Attenuon, Llc Cell surface tropomyosin as a target of angiogenesis inhibition
CN1858243A (zh) 2005-04-30 2006-11-08 安徽省生物医学研究所 一种预测血管紧张素ii受体拮抗剂类降压药药物作用的方法及其应用
EP2216651A4 (en) * 2007-10-18 2010-12-01 Miyazaki Prefectural Ind Suppo BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE
AU2009269257A1 (en) 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Method for detection of fibromyalgia
GB0821721D0 (en) 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
ES2529101T3 (es) 2009-03-30 2015-02-16 Nordic Bioscience A/S Ensayo de biomarcadores para fibrosis
JP5714285B2 (ja) 2010-09-29 2015-05-07 株式会社プロトセラ 妊娠高血圧症候群マーカーおよびそれを用いた診断
CN102558329A (zh) 2010-12-10 2012-07-11 中国人民解放军军事医学科学院生物医学分析中心 一组特异性多肽及其在制备肺癌早期诊断试剂中的用途
RS57413B1 (sr) 2012-03-28 2018-09-28 Sanofi Sa Antitela za ligande bradikinin b1 receptora
WO2014113712A1 (en) * 2013-01-20 2014-07-24 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
JP2016188761A (ja) 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
WO2015120036A1 (en) * 2014-02-04 2015-08-13 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
CN104155457B (zh) 2014-08-22 2016-11-16 北京蛋白质组研究中心 一种结直肠癌相关“多肽-蛋白组合式标志物”检测试剂盒
CN104345154B (zh) 2014-08-22 2016-10-26 北京蛋白质组研究中心 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒
WO2016081413A1 (en) * 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Also Published As

Publication number Publication date
JP7425117B2 (ja) 2024-01-30
JP2024026847A (ja) 2024-02-28
JP2019505185A (ja) 2019-02-28
AU2022204058A1 (en) 2022-06-30
NZ743482A (en) 2023-04-28
AU2025200412A1 (en) 2025-02-13
CO2018007216A2 (es) 2018-09-20
WO2017106504A8 (en) 2017-07-13
EP3390439B1 (en) 2025-03-12
US20210025898A1 (en) 2021-01-28
KR20180134838A (ko) 2018-12-19
AU2022204058B2 (en) 2024-10-31
EP4597115A2 (en) 2025-08-06
JP2025188193A (ja) 2025-12-25
IL322971A (en) 2025-10-01
MX2023000773A (es) 2023-02-22
AU2016372159A1 (en) 2018-07-05
WO2017106504A1 (en) 2017-06-22
AU2016372159B2 (en) 2022-03-24
IL259995B2 (en) 2023-05-01
IL312919B2 (en) 2026-02-01
IL259995A (en) 2018-07-31
US20230408528A1 (en) 2023-12-21
US20250172567A1 (en) 2025-05-29
CN108602877A (zh) 2018-09-28
IL297850B2 (en) 2024-10-01
IL259995B1 (en) 2023-01-01
KR102874711B1 (ko) 2025-10-23
JP2022141640A (ja) 2022-09-29
IL312919B1 (en) 2025-10-01
EP3390439A1 (en) 2018-10-24
EA201891414A1 (ru) 2019-02-28
US11668718B2 (en) 2023-06-06
JP7092669B2 (ja) 2022-06-28
EP4597115A3 (en) 2025-08-13
IL297850B1 (en) 2024-06-01
KR20240161708A (ko) 2024-11-12
IL297850A (en) 2023-01-01
JP7758766B2 (ja) 2025-10-22
KR102728491B1 (ko) 2024-11-13
CA3008621A1 (en) 2017-06-22
BR112018012165A2 (pt) 2018-12-04
IL312919A (en) 2024-07-01
US12135329B2 (en) 2024-11-05

Similar Documents

Publication Publication Date Title
MX2018007493A (es) Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido.
CY1125705T1 (el) Πρωτεϊνες προσδεσης καλλικρεϊνης πλασματος
MX2022007861A (es) Bibliotecas de polipeptidos modulares y metodos para elaborarlas y usarlas.
CY1124465T1 (el) Ανοσοδιαμορφωτικες πρωτεϊνες με συντονιζομενες συγγενειες
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
EA201592263A1 (ru) Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
EA201792307A1 (ru) Способы репарации и регенерации тканей
MX2022000302A (es) Moleculas de union que inhiben el crecimiento del cancer.
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
MX342171B (es) Peptido o complejo peptidico que se une a integrina ?2 y metodos y usos que implican a los mismos.
NI201200080A (es) Antagonistas de il-17a
CL2019000694A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal.
MX2018013341A (es) Analisis de macromoleculas que emplea la codificacion de acido nucleico.
EA201891293A1 (ru) Мультиспецифические антитела
MX2022008073A (es) Anticuerpos dirigidos a los huesos.
MX2016006529A (es) Anticuerpos dobles especificos.
AR089934A1 (es) Analisis de datos de secuencias de adn
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
BR112015013515A2 (pt) métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica
CO6700829A2 (es) Moduladores novedosos y métodos de uso
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MX2021008216A (es) Anticuerpos anti-tigit.
BR112017015746A2 (pt) detector de campo magnético de dnv